Harwood Feffer LLP (www.hfesq.com)
is investigating potential claims against the board of directors of
TomoTherapy Incorporated ("TomoTherapy" or the "Company") (NASDAQ:TOMO -
News) concerning the sale of the Company to Accuray Incorporated
("Accuray”) in a transaction valued at $277 million.
Under the terms of the agreement, TomoTherapy shareholders would receive
$3.15 in cash and 0.1648 shares of Accuray stock for every share of
TomoTherapy common stock they own or $4.80 per share. Our investigation
concerns whether the board of directors is undertaking a fair process to
obtain fair consideration for all shareholders of TomoTherapy.
If you own shares of TomoTherapy and would like to learn more about
these claims or if you wish to discuss this matter and have any
questions or information concerning this announcement, please contact
Daniella Quitt, Esq. at dquitt@hfesq.com
or Matthew M. Houston, Esq. at mhouston@hfesq.com.
You may also call them at (877) 935-7400. For more information about
class actions, or to sign up online, please visit our website: www.hfesq.com.
Harwood Feffer LLP is a national shareholder litigation firm. Harwood
Feffer LLP is devoted to protecting the interests of individual and
institutional investors in shareholder actions in state and federal
courts nationwide.
Attorney Advertising. © 2011 Harwood Feffer LLP. The law firm
responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com).
Prior results do not guarantee or predict a similar outcome with respect
to any future matter.
